-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths.
At this stage, there are still no early imaging biomarkers that can accurately assess the efficacy and tumor response in the early stage of treatment.
Recently, a study published in the journal European Radiology compared the 1D and 3D quantitative tumor response criteria of DCE-MRI in patients with advanced liver cancer treated with sorafenib to predict the overall survival (OS) in the early stage of treatment.
This retrospective study included 29 patients with advanced HCC who had been treated with sorafenib for at least 60 days.
This retrospective study included 29 patients with advanced HCC who had been treated with sorafenib for at least 60 days.
Kaplan-Meier analysis showed that the stratification of DC vs.
Figure 1 The first FU time point after the start of systemic treatment with sorafenib uses the previously validated cut-off value, based on the target lesion response measured by (a) RECIST, (b) mRECIST, (c) %qEASL and (d) vqEASL Survival analysis performed.
Figure 1 The first FU time point after the start of systemic treatment with sorafenib uses the previously validated cut-off value, based on the target lesion response measured by (a) RECIST, (b) mRECIST, (c) %qEASL and (d) vqEASL Survival analysis performed.
Figure 2 The waterfall chart shows the changes of (a) RECIST, (c) mRECIST, (e)%qEASL and (g) vqEASL for each analyzed lesion (n=46), and according to (b) RECIST, (d) mRECIST, (f) The absolute changes of %qEASL and (h) vqEASL are stratified.
Figure 2 The waterfall chart shows the changes of (a) RECIST, (c) mRECIST, (e)%qEASL and (g) vqEASL for each analyzed lesion (n=46), and according to (b) RECIST, (d) mRECIST, (f) The absolute changes of %qEASL and (h) vqEASL are stratified.
This study determined that the enhanced vqEASL and mRECIST were reliable predictors of survival rates for patients in the early stage after the start of sorafenib treatment.
Original source:
Luzie A Doemel,Julius Chapiro,Fabian Laage Gaupp,et al.
Luzie A Doemel,Julius Chapiro,Fabian Laage Gaupp,et al.
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
DOI: org/10.
1007/s00330-020-07381-9">10.
1007/s00330-020-07381-9org/10.
1007/s00330-020-07381-9"> 10.
1007/s00330-020-07381-9 Leave a message here
